A. Salama

发表

A Review of Immune-Mediated Adverse Events in Melanoma

L. Kennedy, A. Salama, L. B. Kennedy, 2019, Oncology and Therapy.

Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations

A. Salama, M. J. Grant, N. DeVito, 2018, Melanoma management.

Mind-mapping for lung cancer: Towards a personalized therapeutics approach

R. Salgia, T. Hensing, A. Husain, 2011, Advances in therapy.

Operative and peri‐operative considerations in the management of brain metastasis

C. R. Goodwin, A. Salama, Eric W. Sankey, 2019, Cancer medicine.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Wei Zhou, Dirk Schadendorf, Reinhard Dummer, 2015, The Lancet. Oncology.

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

A. Halpern, S. Swetter, M. Ross, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

A tumor-intrinsic PD-L1-NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.

Douglas B. Johnson, J. Balko, A. Nixon, 2020, The Journal of clinical investigation.

A review of cancer immunotherapy toxicity

L. Kennedy, A. Salama, L. B. Kennedy, 2020, CA: a cancer journal for clinicians.

Tumor Heterogeneity and Therapeutic Resistance.

R. Salgia, C. Lovly, A. Salama, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma.

A. Salama, B. Howard, B. Hanks, 2020, Surgical oncology.

Overall Survival Improved for Contemporary Patients with Melanoma: A 2004–2015 National Cancer Database Analysis

A. Salama, G. Beasley, N. Farrow, 2020, Oncology and Therapy.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

F. Hodi, H. Kluger, M. Postow, 2017, Journal of immunotherapy.

Melanoma, version 4.2014.

A. Halpern, S. Swetter, M. Ross, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Embracing rejection: Immunologic trends in brain metastasis

K. Blackwell, J. Kirkpatrick, Grace J. Kim, 2016, Oncoimmunology.

Next Steps in Immuno-Oncology: Enhancing Antitumor Effects Through Appropriate Patient Selection and Rationally Designed Combination Strategies.

S. Moschos, A. Salama, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy

A. Salama, N. DeVito, M. Plebanek, 2020, Cell reports.

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

A. Salama, M. Malinzak, Irena Tan, 2018, Journal of Immunotherapy for Cancer.

Immune Checkpoint Inhibition

J. Crawford, A. Salama, S. Sammons, 2018 .

Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study.

K. Patel, K. Roy Choudhury, A. Salama, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.

A. Terando, A. Salama, Michael C. Brown, 2019, The Journal of surgical research.

Neoadjuvant use of ipilimumab in locally advanced melanoma

L. Howie, D. Tyler, A. Salama, 2015, Journal of surgical oncology.

Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events

D. Ko, T. Haykal, A. Salama, 2022, Journal of immunotherapy.

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

Elizabeth A. Scoville, R. Sullivan, J. Sosman, 2021, Oncoimmunology.

Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics

T. Olencki, E. Hade, A. Gangi, 2017, International journal of surgery. Oncology.

Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma

G. Linette, C. Horak, J. Wolchok, 2017 .

Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.

A. Salama, B. Andonian, J. Choe, 2016, Immunotherapy.

Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab.

Rosie Qin, N. Bhavsar, A. Salama, 2016, International journal of radiation oncology, biology, physics.

Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With

Rosie Qin, N. Bhavsar, A. Salama, 2016 .

Ipilimumab-associated lymphocytic colitis: a case report

A. Salama, N. Ferguson, R. Burbridge, 2015 .

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis

A. Salama, B. Hanks, A. Bostwick, 2015, Journal of Immunotherapy for Cancer.

Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma

D. Tyler, M. Morse, A. Salama, 2014, Annals of Surgical Oncology.

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

A. Hauschild, D. Schadendorf, R. Dummer, 2016, European journal of cancer.

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

R. Sullivan, R. Dummer, J. Kirkwood, 2021, The New England journal of medicine.

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2015, Journal of Translational Medicine.

Melanoma, version 2.2016 clinical practice guidelines in oncology

A. Halpern, S. Swetter, M. Ross, 2016 .

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

G. Linette, C. Horak, J. Wolchok, 2015, The New England journal of medicine.

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors

D. Leaf, D. Iberri, Douglas B. Johnson, 2019, American journal of hematology.

NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019.

S. Swetter, M. Ross, J. Sosman, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Neuro-ophthalmic side effects of molecularly targeted cancer drugs

A. Salama, M. Bhatti, A. Salama, 2018, Eye.

First-line treatment of metastatic melanoma: role of nivolumab

A. Salama, J. Force, 2017, ImmunoTargets and therapy.

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

S. Swetter, M. Ross, J. Sosman, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

G. Linette, C. Horak, J. Wolchok, 2016, The Lancet. Oncology.

Advances in targeted therapy for melanoma: a focus on MEK inhibition

Kevin B. Kim, A. Salama, 2014 .

Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma

A. Salama, 2013, Clinical Medicine Insights. Oncology.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

D. Schadendorf, P. Ascierto, R. Dummer, 2017, European journal of cancer.

Updates in Therapy for Advanced Melanoma

A. Salama, B. Singh, 2016, Cancers.

Advanced Melanoma: Resistance Mechanisms to Current Therapies.

Douglas B. Johnson, A. Salama, A. Haugh, 2021, Hematology/oncology clinics of North America.

Immune Checkpoint Blockade: The New Frontier in Cancer Treatment

D. George, A. Salama, J. Clarke, 2018, Targeted Oncology.

Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies

S. Moschos, A. Salama, April K. S. Salama, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma

R. Sullivan, J. Wolchok, M. Atkins, 2016, Cancer.

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma

A. Salama, Michael C. Brown, G. Beasley, 2021, Human vaccines & immunotherapeutics.

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

G. Linette, F. Haluska, D. Niedzwiecki, 2012, Journal of Translational Medicine.

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

G. Linette, F. Haluska, D. Niedzwiecki, 2006, Journal of Translational Medicine.

Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma.

D. Tyler, H. Seigler, A. Salama, 2014, Journal of the American College of Surgeons.

Plasma Cytokine Analysis in Patients with Advanced Extremity Melanoma Undergoing Isolated Limb Infusion

D. Tyler, Cliburn Chan, A. Salama, 2013, Annals of Surgical Oncology.

Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.

G. Linette, C. Horak, J. Wolchok, 2015 .

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database

Eneida A. Mendonça, Ravi Salgia, Rifat Hasina, 2011, Journal of Clinical Bioinformatics.

Metastatic Uveal Melanoma—A Review of Current Therapies and Future Directions

A. Salama, E. Kinsey, 2017 .

Cutaneous Melanoma , Version 2 . 2019

S. Swetter, M. Ross, J. Sosman, 2019 .

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

F. Hodi, S. O’Day, T. Guthrie, 2016, Journal of Immunotherapy for Cancer.

Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis

T. Jaffe, A. Salama, B. Howard, 2016, Abdominal Radiology.

Cytotoxic T-Lymphocyte–Associated Antigen-4

F. Hodi, A. Salama, S. Hodi, 2007, Clinical Cancer Research.

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma

Sin-Ho Jung, D. Bigner, M. Selim, 2021, Journal for ImmunoTherapy of Cancer.

NCCN Guidelines® insights: Melanoma, version 3.2016: Featured updates to the NCCN Guidelines

Brian R. Gastman, Kenneth K. Tanabe, Christopher K. Bichakjian, 2016 .

The Effect of Metastatic Site and Decade of Diagnosis on the Individual Burden of Metastatic Melanoma: Contemporary Estimates of Average Years of Life Lost

Amy P Abernethy, A. Abernethy, D. Tyler, 2012, Cancer investigation.

Personalized treatment of lung cancer.

M. Maitland, R. Salgia, T. Hensing, 2011, Seminars in oncology.

Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma

D. Brizel, D. Tyler, D. Yoo, 2020, Clinical Cancer Research.

Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma

Sin-Ho Jung, L. Ho, A. Salama, 2020, AntiCancer Research.

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.

R. Gray, K. Flaherty, L. Rubinstein, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma

Douglas B. Johnson, P. Ott, L. Hart, 2019, Cancer.

Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.

Melissa L. Johnson, T. Owonikoko, I. Lowy, 2017 .

Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus.

Rosie Qin, A. Salama, 2015, Melanoma management.

MEK Inhibition in the Treatment of Advanced Melanoma

Kevin B. Kim, A. Salama, 2013, Current Oncology Reports.

BRAF in Melanoma: Current Strategies and Future Directions

K. Flaherty, A. Salama, 2013, Clinical Cancer Research.

Trametinib (GSK1120212) in the treatment of melanoma

Kevin B. Kim, A. Salama, April K S Salama, 2013, Expert opinion on pharmacotherapy.

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.

S. Swetter, M. Ross, J. Sosman, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Hazard-Rate Analysis and Patterns of Recurrence in Early Stage Melanoma: Moving towards a Rationally Designed Surveillance Strategy

A. Abernethy, D. Tyler, A. Salama, 2013, PloS one.

Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2016 .

Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

D. Tyler, A. Salama, G. Beasley, 2017, Expert opinion on pharmacotherapy.

Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma.

A. Salama, L. Vahdat, S. Sammons, 2016, Melanoma management.

Updates in adjuvant systemic therapy for melanoma

C. Slingluff, A. Salama, B. Hanks, 2018, Journal of surgical oncology.

Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab.

Rosie Qin, J. Kirkpatrick, A. Salama, 2016, Melanoma management.

Irradiation and immunotherapy: From concept to the clinic

M. Postow, A. Salama, J. Salama, 2016, Cancer.

Current multidisciplinary management of brain metastases

C. Anders, J. Kirkpatrick, J. Sampson, 2020, Cancer.

Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma

T. Jaffe, D. Tyler, A. Salama, 2016, Annals of Surgical Oncology.

Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).

G. Linette, J. Wolchok, F. Hodi, 2016 .

A Multicenter Prospective Evaluation of the Clinical Utility of F-18 FDG-PET/CT in Patients With AJCC Stage IIIB or IIIC Extremity Melanoma

A. Abernethy, D. Tyler, G. Broadwater, 2012, Annals of surgery.

NCCN Guidelines Insights: Melanoma, Version 3.2016.

Merrick I Ross, Susan M Swetter, Brian Gastman, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

L. G. Moss, C. Mathews, A. Salama, 2016, Journal of Immunotherapy for Cancer.

Oncotargets and Therapy Dovepress Clinical Applications of Pd-1-based Therapy: a Focus on Pembrolizumab (mk-3475) in the Management of Melanoma and Other Tumor Types

A. Salama, T. Gangadhar, 2022 .

Potential Utility of Synthetic D-Lactate Polymers in Skin Cancer

Jennifer Y. Zhang, A. Salama, G. Beasley, 2021, JID innovations.

Mind the gap: Gendered publication trends in oncology

A. Salama, M. Palta, G. Beasley, 2020, Cancer.

Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.

R. Gray, K. Flaherty, L. Rubinstein, 2019, Journal of Clinical Oncology.

Tumor Heterogeneity and Therapeutic Resistance.

R. Salgia, C. Lovly, A. Salama, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma.

C. Barker, A. Salama, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Cutaneous Melanoma: Management of Melanoma Brain Metastases and Molecular Testing

S. Swetter, Douglas B. Johnson, A. Salama, 2021, Journal of the National Comprehensive Cancer Network.

MET and phosphorylated MET as potential biomarkers in lung cancer.

Ravi Salgia, Theodore Karrison, Maria Tretiakova, 2011, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).

F. Hodi, T. Guthrie, A. Salama, 2015 .

Radiosurgery for Brain Metastases in Melanoma Patients Receiving Ipilimumab

Rosie Qin, N. Bhavsar, J. Kirkpatrick, 2015 .

Paraneoplastic Production of Granulocyte-macrophage Colony-stimulating Factor and Granulocyte Colony-stimulating Factor in a Case of Rapidly Progressing Cutaneous Squamous Cell Carcinoma

A. Salama, N. DeVito, E. Kinsey, 2016 .

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2015, Journal of Translational Medicine.

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

P. Ascierto, J. Kirkwood, A. Shoushtari, 2023, Journal for ImmunoTherapy of Cancer.

A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.

Douglas B. Johnson, P. Ott, L. Hart, 2017 .

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types

A. Salama, T. Gangadhar, 2015, OncoTargets and therapy.

Oncotargets and Therapy Dovepress Clinical Applications of Pd-1-based Therapy: a Focus on Pembrolizumab (mk-3475) in the Management of Melanoma and Other Tumor Types

A. Salama, T. Gangadhar, 2022 .

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec

A. Salama, P. Mosca, Khushnood Faraz, 2023, JAAD case reports.

NCCN Guidelines Insights: Melanoma, Version 3.2016.

S. Swetter, M. Ross, J. Torres-Roca, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Irradiation and immunotherapy: From concept to the clinic

M. Postow, A. Salama, J. Salama, 2016, Cancer.

Next Steps in Immuno-Oncology: Enhancing Antitumor Effects Through Appropriate Patient Selection and Rationally Designed Combination Strategies.

S. Moschos, A. Salama, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)

G. Linette, C. Horak, J. Wolchok, 2016 .